Papers matching “transplant-eligible patients” 38
Not finding it? Sign in to also search OpenAlex live.
-
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Hervé Avet‐Loiseau, Pieter Sonneveld, Philippe Moreau, Fritz C. Offner, Vincent H. J. van der Velden, Denis Caillot, +25 more
21citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations -
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study
Cyrille Hulin, Fritz C. Offner, Philippe Moreau, Murielle Roussel, Karim Belhadj, Lotfi Benboubker, +17 more
54citations -
Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, Phoebe Joy Ho, Meral Beksaç, +38 more
1citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +21 more
24citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Larry Don Anderson, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, +21 more
3citations -
MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)2024 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Meletios Athanasios Dimopoulos, Pieter Sonneveld, Paula Rodríguez‐Otero, Hang Quach, P. Joy Ho, Meral Beksaç, +33 more
3citations -
MM-350: Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN2020 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej J. Jakubowiak, Leyla Osman Shune, Ashraf Z. Badros, +8 more
3citations -
Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies
Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, +24 more
9citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jacob P. Laubach, Jonathan L. Kaufman, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +22 more
24citations -
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Marc Steffen Raab, Niels Weinhold, Klaus Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, +23 more
47citations -
Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
Pieter Sonneveld, María‐Victoria Mateos, Adrián Macías Alegre, Thierry T.F. Facon, Cyrille Hulin, Mahmoud Hashim, +6 more
2citations -
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial2024 Journal of Clinical Oncology article Medicine Multiple Myeloma Research and Treatments Open access
Elias Karl Mai, Uta Bertsch, Ema Požek, Roland R. Fenk, Britta Besemer, Christine Hanoun, +71 more
80citations -
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
Philippe Moreau, Cyrille Hulin, Sonja Zweegman, Mahmoud Hashim, Yannan Hu, Bart M. S. Heeg, +7 more
6citations -
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Pieter Sonneveld, Philippe Moreau, Meletios Athanasios Dimopoulos, Hang Quach, P. Joy Ho, Meral Beksaç, +35 more
0citations -
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 1 patent
Murielle Roussel, Philippe Moreau, Benjamin Hébraud, Kamel Laribi, Arnaud Jaccard, Mamoun Dib, +15 more
36citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
18citations -
Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
Sarah Gillessen, Andreas Hüttmann, Vladan Vučinić, Horst Müller, Annette Plütschow, Andreas Viardot, +13 more
5citations -
Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022
Conal Houstoun, Patrick John Hayden, Dirk‐Jan Eikema, Linda Köster, Sandra Sauer, Annoek E. C. Broers, +19 more
0citations